Evidence on the economic impact of clinical trials and cost.

Background

"The analysis team is responsible for two datasets on life sciences activity in the UK and how it compares with other countries. One of its publications, the Bioscience and health technology sector statistics, is an official statistic and captures a detailed breakdown of where life sciences activity occurs in the UK, as well as key economic indicators such as employment and turnover. The analysis team is also responsible for publishing the Life sciences competitiveness indicators, a publication which tracks UK performance against international comparators. These two publications form the bulk of the evidence base that supports OLS policy making and key facts and figures for stakeholders. One of the ambitions of the team is to expand the range of data collected on activity in the sector to encompass a broader range of economic indicators, including Gross Value Added, R&D spending, Wages, and workforce statistics, among others.

In addition to this critical evidence base, OLS is also interested in key research questions and evidence to support the development of policy for the Life Sciences Missions, a set of disease and intervention areas identified in the Life Sciences Vision as key areas of intervention to help the NHS to solve some of the biggest healthcare problems of our generation. These range from establishing a strong evidence base on incidence and its regional distribution to identifying potential innovative technologies that could address them. Additionally, the analysis team is also very interested in deepening our understanding of the economic impact and possibilities of the broad area of genomics, as well as understanding the economic impacts and societal benefits that accrue from conducting clinical trials and other forms of R&D in the life sciences.

On the regulatory front, OLS would like to expand its understanding of the main regulatory barriers to the approval and roll-out of new, innovative technologies, as well as understanding the costs and benefits associated with these regulations. We have a limited evidence base for some products but would like to expand that understanding to be better able to assess the impact of specific regulatory interventions. We would also like to have more comprehensive data on the introduction and adoption of these technologies across the country and through the NHS.

On the investment front, we are particularly interested in building a more comprehensive evidence base on the determinants of investment in both manufacturing and R&D facilities, and how elements of both the commercial and business environment affects company location and investment decisions.

Finally, we are very interested in developing a more comprehensive understanding of the manufacturing landscape in the UK, from being able to interrogate the pipeline of new products and innovations in development, to establishing the UK’s manufacturing capabilities for health and supply chain resilience, as well as understanding key challenges faced by companies in terms of access to skilled workers and finance across the country."

Next steps

If you are keen to register your interest in working and connecting with DSIT Digital Technology and Telecoms Group and/or submitting evidence, then please complete the DSIT-ARI Evidence survey - https://dsit.qualtrics.com/jfe/form/SV_cDfmK2OukVAnirs.
Please view full details: https://www.gov.uk/government/publications/department-for-science-innovation-and-technology-areas-of-research-interest/dsit-areas-of-research-interest-2024

Related UKRI funded projects


  • Reliable and Efficient Estimation of the Economic Value of medical Research (REEEVR)

    In the UK, taxpayers and charities pay for most healthcare research. National bodies like the National Institute for Health Research (NIHR) allocate public funds. Charities like Cancer Research UK (CRUK) rely on donation...

    Funded by: MRC

    Lead research organisation: University of Bristol

    Why might this be relevant?

    The project focuses on estimating the economic value of medical research, including cost-effectiveness analysis and funding decisions, which directly relates to the economic impact of clinical trials and costs.

  • Launchpad Cluster Management - Northern Ireland

    The Northern Ireland (NI) Health and Life Sciences (HLS) sector presents an emerging cluster combining expertise, infrastructure, academia and industry across a DBT designated area of High Potential Opportunity: in Preci...

    Funded by: Innovate UK

    Lead research organisation: HEALTH INNOVATION RESEARCH ALLIANCE

    Why might this be relevant?

    Partially relevant as it focuses on the economic impact of the life sciences sector in Northern Ireland, but does not specifically address clinical trials and cost.

  • Clinical Research Infrastructure and Trials Platform

    The opportunity is to enable the Clinical Trials Units at UoW and UoB to increase the region's market share in clinical trials. The UK Science base is recognised as internationally excellent and the ; j translation of th...

    Funded by: Innovate UK

    Lead research organisation: UNIVERSITY OF WARWICK

    Why might this be relevant?

    The project addresses the need for more efficient R&D processes and increased clinical trials activity, which is related to the economic impact of clinical trials and research.

  • Better measurement of the complementarity between UK public, charity and private medical research

    Getting benefits from medical research in terms of preventing or treating illness, advancing scientific knowledge and generating economic wealth often, though not always, involves private industry. The private sector bui...

    Funded by: MRC

    Lead research organisation: King's College London

    Why might this be relevant?

    The project aims to measure the complementarity between public, charity, and private medical research funding, which is relevant to understanding the economic impact of clinical trials and research.

  • British Regen Industry Tool Set (BRITS)

    The British Regen Industry Tool Set (BRITS) is an industry driven project aimed at establishing reliable market data and creating both detailed bioprocess economics models and higher level business models for integration...

    Funded by: Innovate UK

    Lead research organisation: LONZA BIOLOGICS PLC

  • Real-world data: how can we use it for health technology assessment decision-making?

    Randomised clinical trials (RCTs) are the gold standard of evidence where treatments and therapies are concerned. However, RCTs are often insufficient for HTA purposes. There is a growing interest in using real-world dat...

    Funded by: ESRC

    Lead research organisation: London School of Hygiene & Tropical Medicine

  • Experomental Medicine Network of Excellence

    The UK Science base is recognised as internationally excellent and the translation of this excellence into improvements in clinical practice is essential to ensure the continued delivery of UK economic and health benefit...

    Funded by: Innovate UK

    Lead research organisation: UNIVERSITY OF BIRMINGHAM

  • The UK Regulatory Innovation Network for Advanced Therapies

    Advanced Therapy Medicinal Products (ATMP) are innovative therapies with potential to cure, rather than ameliorate, diseases addressing significant unmet needs. The ATMP field is rapidly evolving and growing, with a stro...

    Funded by: Innovate UK

    Lead research organisation: CELL THERAPY CATAPULT LIMITED

  • Method - Efficient and effective conduct of clinical trials

    Clinical trials help doctors and patients to make better healthcare decisions. The way that a trial is done and the data collected and checked effects the cost of the trial and also directly effects the confidence we can...

    Funded by: MRC

    Lead research organisation: University College London

  • Novel method for tracking the translation processes that lead to impact from Biomedical research - A pilot study

    The MRC Economic Impact call states that "The MRC wishes to understand better the link between research and wider economic and societal impacts, and to use this understanding to improve strategies for the future sup...

    Funded by: MRC

    Lead research organisation: University of Sussex